Format

Send to

Choose Destination
Methods Mol Biol. 2019;1873:279-292. doi: 10.1007/978-1-4939-8820-4_18.

Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases.

Author information

1
Department of Biomedicine, University of Bergen, Bergen, Norway.
2
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway.
3
K. G. Jebsen Centre for Neuropsychiatric Disorders, Bergen, Norway.
4
Department of Biomedicine, University of Bergen, Bergen, Norway. aurora.martinez@uib.no.
5
K. G. Jebsen Centre for Neuropsychiatric Disorders, Bergen, Norway. aurora.martinez@uib.no.

Abstract

Pharmacological chaperones are small molecular weight molecules that bind specifically to protein targets and stabilize unstable and misfolded conformations. In particular, there is an increasing interest in the application of this type of compounds for the correction of genetic conformational disorders, which are caused by mutations leading to protein instability. The discovery of compounds with pharmacological chaperone ability is customarily initiated by a high-throughput screening of chemical libraries searching for stabilizing binders. However, there is no established consensus for the subsequent steps. Therefore, here, we introduce an example of a successful protocol directed to the discovery of pharmacological chaperones with potential for the therapeutic correction of phenylketonuria, a defect caused by mutations in the enzyme phenylalanine hydroxylase.

KEYWORDS:

Drug discovery and development; Functional assays; Orthogonal binding assays

PMID:
30341617
DOI:
10.1007/978-1-4939-8820-4_18
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center